IRIS
PEROSA, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.229
AS - Asia 3.975
EU - Europa 2.998
SA - Sud America 1.059
AF - Africa 105
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 9
Totale 17.388
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.123
SG - Singapore 1.789
CN - Cina 966
BR - Brasile 921
IT - Italia 627
HK - Hong Kong 618
SE - Svezia 531
UA - Ucraina 392
RU - Federazione Russa 388
DE - Germania 340
VN - Vietnam 235
FI - Finlandia 217
GB - Regno Unito 204
FR - Francia 89
IN - India 82
AR - Argentina 64
BD - Bangladesh 51
ID - Indonesia 49
CA - Canada 47
PL - Polonia 36
MX - Messico 35
IE - Irlanda 33
TR - Turchia 30
CI - Costa d'Avorio 28
JP - Giappone 28
BE - Belgio 24
AT - Austria 23
IQ - Iraq 22
EC - Ecuador 21
UZ - Uzbekistan 21
ZA - Sudafrica 21
ES - Italia 20
NL - Olanda 20
MA - Marocco 13
AU - Australia 12
PY - Paraguay 12
CO - Colombia 11
PK - Pakistan 11
IR - Iran 10
DO - Repubblica Dominicana 9
KE - Kenya 9
PE - Perù 9
SA - Arabia Saudita 9
HR - Croazia 8
LT - Lituania 8
RO - Romania 8
VE - Venezuela 8
AZ - Azerbaigian 7
CL - Cile 7
EU - Europa 7
AL - Albania 6
DZ - Algeria 6
EG - Egitto 6
JO - Giordania 5
MY - Malesia 5
TN - Tunisia 5
UY - Uruguay 5
CH - Svizzera 4
CR - Costa Rica 4
PH - Filippine 4
PS - Palestinian Territory 4
AE - Emirati Arabi Uniti 3
BB - Barbados 3
JM - Giamaica 3
MD - Moldavia 3
NP - Nepal 3
SN - Senegal 3
TH - Thailandia 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
GR - Grecia 2
HN - Honduras 2
IL - Israele 2
KR - Corea 2
KZ - Kazakistan 2
LB - Libano 2
MK - Macedonia 2
NG - Nigeria 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CD - Congo 1
CG - Congo 1
CM - Camerun 1
CY - Cipro 1
DJ - Gibuti 1
GA - Gabon 1
IM - Isola di Man 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 17.375
Salva come PNG Salva come JPEG
Città #
Singapore 928
Chandler 927
Jacksonville 912
Fairfield 858
Ashburn 781
Woodbridge 663
Hong Kong 614
Houston 507
Ann Arbor 396
Nyköping 377
Seattle 359
Cambridge 354
Wilmington 324
Bari 314
Beijing 277
Lawrence 200
Roxbury 200
Nanjing 195
New York 151
Des Moines 133
Boardman 129
Los Angeles 125
Princeton 90
Dallas 87
Ho Chi Minh City 79
Inglewood 66
São Paulo 61
Brooklyn 60
Santa Clara 60
Buffalo 55
Nanchang 55
Shenyang 50
Hanoi 49
Hebei 47
London 46
Moscow 42
San Diego 39
Chicago 37
Munich 36
Pune 35
Rio de Janeiro 35
Jiaxing 32
Abidjan 28
Tianjin 28
Tokyo 28
Changsha 26
Dublin 26
Jakarta 25
Brussels 24
Belo Horizonte 23
Guangzhou 23
Helsinki 23
Rome 23
Warsaw 23
Paris 22
Stockholm 22
Denver 19
Noicattaro 19
Tashkent 18
Boston 17
Chennai 17
Curitiba 17
Poplar 17
Atlanta 16
Dong Ket 16
Montreal 16
Porto Alegre 16
Toronto 16
Dearborn 15
Dhaka 15
Washington 15
Brasília 14
Falls Church 14
Marseille 14
Nuremberg 14
Vienna 14
Grafing 13
Orem 13
San Francisco 13
Auburn Hills 12
Council Bluffs 12
Johannesburg 12
Radomsko 12
Amsterdam 11
Buenos Aires 11
Columbus 11
Haiphong 11
Mexico City 11
Milan 11
Phoenix 11
The Dalles 11
Campinas 10
Frankfurt am Main 9
Sydney 9
Ankara 8
Campo Grande 8
Falkenstein 8
Goiânia 8
Guarulhos 8
Hefei 8
Totale 11.699
Salva come PNG Salva come JPEG
Nome #
Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association 184
CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading 170
Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin 161
Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis 160
CD20-depleting therapy in autoimmune diseases: from basic research to the clinic 158
Autoantibodies Recognizing the Amino Terminal 1-17 Segment of CENP-A Display Unique Specificities in Systemic Sclerosis 158
Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study 158
Antibody V(h) repertoire differences between resolving and chronically evolving hepatitis C virus infections 154
MHC Class i Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells 150
CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases 147
Autoantibodies to intracellular antigens: generation and pathogenetic role 147
Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma 146
Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease 142
AB0695 Subspecificities of Anti-Centromeric-Associated Protein a (CENP-A) Antibodies (AB) Can Identified a Subset of Patients at Higher Risk of Developing Pulmonary Hypertension 139
Absence of streptococcal protein G (PG)-specific determinant in the Fab region of human IgG2 134
Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis 134
CD20 mimicry by a mAb rituximab-specific linear peptide: A potential tool for active immunotherapy of autoimmune diseases 132
Oxidized low density lipoproteins: The bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders. 132
Serum levels of beta-2-microglobulin-free heavy chain of HLA class I antigen in healthy individuals: relationship to their class I allotype 131
Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart? 124
Serological methods to detect anti-idiotypic antibodies 122
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 122
Antiphospholipids syndrome complicated by a systemic capillary leak-like syndrome treated with steroids and intravenous immunoglobulins a case report 122
Vasculitides: Proposal for an integrated nomenclature 121
CD20 mimicry by mAb Rituximab-specific linear peptide. A potential tool for active immunotherapy of autoimmune diseases 118
Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature 116
Rheumatic disorders as paraneoplastic syndromes 114
CD20: A target antigen for immunotherapy of autoimmune diseases 113
Human CD4 internal antigen anti-idiotypic monoclonal antibody. Immunochemical and sequence analysis 113
Effects of Adjuvants for Human Use in Systemic Lupus Erythematosus (Sle)-Prone (Nzb/Nzw) F1 Mice 113
Extra-articular manifestations of rheumatoid arthritis: an update 113
Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor 111
A sandwich assay to detect and characterize syngeneic anti-idiotypic antibodies to murine anti-HLA and tumor associated antigen monoclonal antibodies 111
Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma 111
Analisi molecolare di un anticorpo monoclonale (ACMO) anti-idiotipo 'immagine interna' dell'antigene CD4 110
Cinetica di produzione e clonotipia di anticorpi anti-anti-idiotipo (Ac3) in due pazienti affette da patologia autoimmune immunizzate con un anticorpo monoclonale anti-idiotipo (AcMo2) 109
Anti-carbamylated protein antibodies in patients with systemic sclerosis: an intriguing association with skin involvement 108
Preparation, characterization and utilization of monoclonal antibodies to the gene products of the HLA-D region with special emphasis on those to polymorphic determinants 106
Amyloidosis: clinical picture, immunological and biomolecular features, treatment prospects 106
B-T cell interaction in the pathogenesis of HCV-positive mixed cryoglobulinemia. 106
Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease 106
Subclinical and clinical atherosclerosis in rheumatoid arthritis: Results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study 106
Identification of an antigenic and immunogenic motif expressed by two 7-Mer Rituximab-specific cyclic peptides 103
Alternative splicing of HLA-C mRNA in HCV-infected hepatocytes reduces viral epitope-specific cytotoxicity T cell response and promotes NK activity 103
Amyloidosis: clinical picture, immunological and biomolecular features, treatment prospects 101
The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3) 100
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 100
Increased serum levels of beta2m-free HLA class I heavy chain in multiple myeloma 99
Syngeneic polyclonal and monoclonal antiidiotypic antibodies to murine anti-human high molecular weight-melanoma associated antigen and anti-HLA monoclonal antibodies 99
The Fab region of IgG2 human myeloma proteins does not bear the streptococcal protein G-specific determinant 99
Macrophage activation syndrome in patients affected by adult-onset still disease: Analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in reumatologia clinica e sperimentale cohort 99
Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes 97
Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors 97
Immunogenicity of two idiotypes with a different immunoglobulin-chain distribution expressed on the same anti-CD4 Mab 96
Syngeneic antiidiotypic monoclonal antibodies to the murine anti-HLA- DR,DP monoclonal antibody CR11-462 95
Immunochemical and functional characterization of anti-idiotypic antibodies to a mouse anti-CD4 monoclonal antibody 95
Beta2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide 94
Size variants of beta-2-microglobulin-free human leucocyte antigen class I heavy chain make different contributions to its serum increase in multiple myeloma 94
Evaluation of biotinylated cells as a source of antigens for characterization of their molecular profile 92
SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? 92
Response to "Is active acid sphingomyelinase required for the antiproliferative response to rituximab?" [e-letter]. http://bloodjournal.hematologylibrary.org/content/117/13/3695.citation/reply#bloodjournal_el_2268 91
Beta2-m-free heavy chain levels of HLA-class I antigen combined with serum IgM or platelet count provide two reliable staging systems in multiple myeloma 91
B2 microglobulin-free heavy chain (FHC) of HLA class I antigen in patients with Hodgkin’s and non Hodgkin’s lymphomas 91
Analysis of beta-2 microglobulin (b2M), free HLA class I heavy chain (FHC) and the associated protein pattern in multiple myeloma (MM) patients from the Nordic Myeloma Group Study #5/94. Haematologica-the Hematology Journal 91
Sars-cov-2 inflammatory syndrome. Clinical features and rationale for immunological treatment 91
Murine antiidiotypic monoclonal antibodies that bear the internal image of HLA-DR allospecificities 90
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management 89
Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: Putative implication of a low anti-carbamylated protein antibodies prevalence 89
L'AMILOIDOSI: QUADRI CLINICI, CARATTERISTICHE IMMUNOLOGICHE E BIOMOLECOLARI, PROSPETTIVE TERAPEUTICHE 88
Anti-idiotypic antibodies in therapy: current status and prospects 87
Anticorpi monoclonali nell'immunoterapia delle malattie autoimmuni 87
Anti-idiotypic monoclonal antibodies (mAb) to an anti-CD4 mAb induce CD4+ T cell depletion in rabbit 86
Soluble CD4 antigen reactivity in intravenous immunoglobulin preparations: is it specific? 86
Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort 86
Analisi della risposta immune indotta da anticorpi monoclonali murini anti-idiotipo (Ab2) anti-CD4 in un sistema xenogenico 85
Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: Implication for peptide-based active immunotherapy 85
Analisi della risposta immune indotta da anticorpi monoclonali murini anti-idiotipo (Ab2) anti-CD4 in un sistema xenogenico 83
Human anti-mouse antibodies interfere in the determination of sCD4 in intravenous immunoglobulin preparations 83
Analysis in a syngeneic and xenogeneic system of mouse antiidiotypic (Ab2) monoclonal antibodies (mAb) elicited with the syngeneic anti-CD4 mAb HP2/6 83
Characterization of the specificity of the Human scFv W9 83
Purification of human immunoglobulins by sequential precipitation with caprylic acid and ammonium sulphate 83
Antigenic mimicry by linear peptides of the conformational epitope recognized by the anti-CD20 monoclonal antibody (mAb) Rituximab 82
Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count 82
Human CD4 "internal antigen" mimicry by anti-idiotypic monoclonal antibodies 82
Anticorpi anti-DNA e network idiotipico nel LES: recenti progressi e prospettive terapeutiche 81
Vaccination against CD20 mimotope peptiide. Is it a feasible strategy for the treatment of autoimmune diseases? 80
Analisi molecolare di un anticorpo monoclonale (AcMo) anti-idiotipo “immagine interna” dell’antigene CD4 80
Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification 80
Identificazione del peptide che mima l'epitopo localizzato sulla catena pesante HLA-I non associata alla beta 2-microglobulina, riconosciuto dall'anticorpo monoclonale HC-10 79
Studi in vitro dell'attivita' antiallergica del Fenoterolo 78
The proliferative transcriptional factor FOXE3 is the target of anti-CENP-A antibodies and identifies a subset of anti-CENP antibody positive systemic sclerosis patients 78
Cloning and chromosomal localization of a cDNA encoding a mitochondrial porin from Drosophila melanogaster 78
Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: Results from a cross-sectional, multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study 78
Uso di un anticorpo monoclonale antiidiotipo di un anticorpo monoclonale anti-CD4 in pazienti con artrite reumatoide 77
null 77
Vasculiti primarie sistemiche 77
Cinetica di produzione e clonotipia di anticorpi anti-anti-idiotipo (Ac3) in due pazienti affetti da patologia autoimmune, immunizzati con un anticorpo monoclonale anti-idiotipo (AcMo2) "Immagine Interna" dell'antigene CD4 76
Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitope 76
Antiidiotype to anti-CD4 monoclonal antibody (mAb) as surrogate of human CD4 antigen (Ag) for active immunotherapy in autoimmune diseases 75
Vasculiti primarie sistemiche 75
Totale 10.512
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.290
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.290
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.112 0 0 0 0 0 95 257 110 223 216 132 79
2021/20221.415 63 209 8 80 77 70 110 86 63 42 236 371
2022/20232.316 340 204 114 226 323 333 36 264 361 28 52 35
2023/2024856 63 140 43 91 65 221 25 66 6 16 39 81
2024/20253.228 99 48 332 77 68 260 249 281 105 155 479 1.075
2025/20263.495 971 270 398 824 756 276 0 0 0 0 0 0
Totale 17.775